MA53689B1 - Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application - Google Patents
Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur applicationInfo
- Publication number
- MA53689B1 MA53689B1 MA53689A MA53689A MA53689B1 MA 53689 B1 MA53689 B1 MA 53689B1 MA 53689 A MA53689 A MA 53689A MA 53689 A MA53689 A MA 53689A MA 53689 B1 MA53689 B1 MA 53689B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- receptor family
- methods
- application
- antibodies against
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001413 cellular effect Effects 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne un anticorps monoclonal humanisé ou son fragment de liaison d'antigène qui se lient spécifiquement à la famille trbv-9 des récepteurs cellulaires t de l'humain. L'invention concerne également un acide nucléique codant pour cet anticorps ou un fragment de liaison à un antigène de celui-ci, un vecteur d'expression, un procédé de production d'un anticorps et l'utilisation d'un anticorps pour traiter des maladies ou des troubles associés à la famille des récepteurs des lymphocytes t humains. L'invention vise notamment la création d'anticorps qui peuvent être utilisés pour la thérapie, notamment lors d'une spondylarthrite ankylosante (sa ou maladie de bechterew), de la la maladie cœliaque et des maladies sanguines malignes dont la pathogenèse est liée à l'implication du récepteur des cellules t trbv9.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018146031A RU2712251C1 (ru) | 2018-12-25 | 2018-12-25 | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| PCT/RU2020/050024 WO2020139175A2 (fr) | 2018-12-25 | 2020-02-20 | Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53689A1 MA53689A1 (fr) | 2022-06-30 |
| MA53689B1 true MA53689B1 (fr) | 2023-03-31 |
Family
ID=69184123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53689A MA53689B1 (fr) | 2018-12-25 | 2020-02-20 | Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12227572B2 (fr) |
| EP (1) | EP3907239A4 (fr) |
| JP (1) | JP2022532274A (fr) |
| KR (2) | KR102788029B1 (fr) |
| CN (2) | CN113646333B (fr) |
| AR (1) | AR117734A1 (fr) |
| AU (1) | AU2020204492A1 (fr) |
| BR (1) | BR112021012555A2 (fr) |
| CA (2) | CA3127767A1 (fr) |
| CL (1) | CL2021001705A1 (fr) |
| CO (2) | CO2021008218A2 (fr) |
| CR (1) | CR20210354A (fr) |
| EA (1) | EA202191813A1 (fr) |
| EC (1) | ECSP21046333A (fr) |
| IL (1) | IL284370A (fr) |
| JO (1) | JOP20210169A1 (fr) |
| MA (1) | MA53689B1 (fr) |
| MX (1) | MX2021007719A (fr) |
| MY (1) | MY205967A (fr) |
| PE (1) | PE20220217A1 (fr) |
| PH (2) | PH12021551775A1 (fr) |
| RU (1) | RU2712251C1 (fr) |
| SG (1) | SG11202106975VA (fr) |
| TW (1) | TW202039574A (fr) |
| WO (2) | WO2020091635A2 (fr) |
| ZA (1) | ZA202104357B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2694412C9 (ru) | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| EP3737692A4 (fr) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (fr) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| WO2021138474A2 (fr) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
| US20240002541A1 (en) * | 2020-12-01 | 2024-01-04 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
| CN116510006A (zh) * | 2022-01-31 | 2023-08-01 | 拜奥卡德联合股份公司 | 抗trbv9抗体的药物组合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
| US5766947A (en) | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| EP2446052B1 (fr) | 2009-06-25 | 2018-08-08 | Fred Hutchinson Cancer Research Center | Procédé de mesure de l'immunité adaptative |
| EP3202784A1 (fr) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | Séquences de récepteurs de lymphocytes t pour une immunothérapie active |
| RU2694412C9 (ru) | 2017-12-25 | 2019-09-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Моноклональные антитела и способы их применения |
| RU2712251C1 (ru) | 2018-12-25 | 2020-01-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения |
-
2018
- 2018-12-25 RU RU2018146031A patent/RU2712251C1/ru active
-
2019
- 2019-12-23 AR ARP190103840A patent/AR117734A1/es unknown
- 2019-12-24 PH PH1/2021/551775A patent/PH12021551775A1/en unknown
- 2019-12-24 KR KR1020217023541A patent/KR102788029B1/ko active Active
- 2019-12-24 TW TW108147432A patent/TW202039574A/zh unknown
- 2019-12-24 WO PCT/RU2019/050258 patent/WO2020091635A2/fr not_active Ceased
- 2019-12-24 CA CA3127767A patent/CA3127767A1/fr active Pending
- 2019-12-24 CN CN201980092905.7A patent/CN113646333B/zh active Active
-
2020
- 2020-02-20 US US17/417,686 patent/US12227572B2/en active Active
- 2020-02-20 WO PCT/RU2020/050024 patent/WO2020139175A2/fr not_active Ceased
- 2020-02-20 JP JP2021537707A patent/JP2022532274A/ja active Pending
- 2020-02-20 MY MYPI2021003585A patent/MY205967A/en unknown
- 2020-02-20 CR CR20210354A patent/CR20210354A/es unknown
- 2020-02-20 CA CA3124813A patent/CA3124813A1/fr active Pending
- 2020-02-20 CN CN202080016346.4A patent/CN114144432A/zh active Pending
- 2020-02-20 MX MX2021007719A patent/MX2021007719A/es unknown
- 2020-02-20 MA MA53689A patent/MA53689B1/fr unknown
- 2020-02-20 PE PE2021001081A patent/PE20220217A1/es unknown
- 2020-02-20 JO JOP/2021/0169A patent/JOP20210169A1/ar unknown
- 2020-02-20 SG SG11202106975VA patent/SG11202106975VA/en unknown
- 2020-02-20 KR KR1020217023568A patent/KR20220131489A/ko active Pending
- 2020-02-20 EA EA202191813A patent/EA202191813A1/ru unknown
- 2020-02-20 BR BR112021012555-8A patent/BR112021012555A2/pt unknown
- 2020-02-20 EP EP20734640.4A patent/EP3907239A4/fr active Pending
- 2020-02-20 AU AU2020204492A patent/AU2020204492A1/en active Pending
-
2021
- 2021-06-23 CO CONC2021/0008218A patent/CO2021008218A2/es unknown
- 2021-06-24 ZA ZA2021/04357A patent/ZA202104357B/en unknown
- 2021-06-24 IL IL284370A patent/IL284370A/en unknown
- 2021-06-24 EC ECSENADI202146333A patent/ECSP21046333A/es unknown
- 2021-06-24 CL CL2021001705A patent/CL2021001705A1/es unknown
- 2021-06-25 PH PH12021551532A patent/PH12021551532A1/en unknown
- 2021-07-23 CO CONC2021/0009689A patent/CO2021009689A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53689A1 (fr) | Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application | |
| MA53688B1 (fr) | Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain | |
| MA50128B1 (fr) | Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation | |
| US10364286B2 (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation | |
| CA3095443A1 (fr) | Procedes a base d'anticorps de detection et de traitement de la maladie d'alzheimer | |
| CN107847595A (zh) | 特异性针对过度磷酸化τ蛋白的抗体及其使用方法 | |
| JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
| KR20190104411A (ko) | 항-pd-l1 항체에 대한 이디오타입 항체 및 이의 용도 | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| CN111518205B (zh) | 人源化抗Aβ单克隆抗体及其应用 | |
| JP2022058881A (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| US20210139568A1 (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
| HK1257425A1 (zh) | 测量因子d活性和因子d抑制剂效力的方法 | |
| CN114578066A (zh) | 检测β-淀粉样蛋白的产品和方法 | |
| CN112153983B (zh) | 抗ngly-1抗体及使用方法 | |
| JP7256172B2 (ja) | ミニブタ試料において抗薬物抗体を決定するための方法 | |
| WO2024012434A1 (fr) | Anticorps, fragment de liaison à l'antigène de celui-ci, et leur utilisation pharmaceutique | |
| CN120209151A (zh) | Gaa单克隆抗体及其应用 | |
| CN119039448A (zh) | 特异性结合抗人tim-3抗体的抗独特型抗体及其用途 | |
| NZ766247B2 (en) | Monoclonal antibodies and methods for using same | |
| JPH06217790A (ja) | 薬物耐性を付与するタンパク質と反応性の抗体およびそれを用いる方法 |